Previous 10 | Next 10 |
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 PR Newswire CRANFORD, N.J. , Oct. 6, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-sta...
Citius Pharmaceuticals ( NASDAQ: CTXR ) on Wednesday said it had submitted a biologics license application (BLA) to the U.S. FDA for its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. According to CTXR, I/ONTAK (denileukin...
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma PR Newswire CRANFORD, N.J. , Sept. 28, 202...
Citius Pharmaceuticals ( NASDAQ: CTXR ), a company focused on critical care products, added ~8% i n the pre-market Friday after announcing a collaboration to advance an investigator-initiated trial on its cancer candidate I/ONTAK for solid tumors. In partnership with Dr....
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial PR Newswir...
Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute Citius Pharmaceuticals, Inc. and its CFO & CBO Jaime Bartushak Honored by Somerset Hills Learning Institute PR Newswire Leading Center for Autism Edu...
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire Chairman & CEO of Citius, Leonard Mazur , to present September 14, 2022 at 11:00am ET CRANFORD, N.J. , Sept. 7, 2022 ...
Citius Pharmaceuticals press release ( NASDAQ: CTXR ): Q3 GAAP EPS of -$0.06. The company has reported $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023 For further details see: Citius Pharmaceuticals G...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update PR Newswire $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023 International si...
Citius Pharmaceuticals ( NASDAQ: CTXR ) on Tuesday said it had held a pre-biologics license application (BLA) meeting with the U.S. FDA to discuss its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. "Based on the FDA's pre-B...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...